Mandate

Vinge advises in the acquisition of Veidekke’s property development operation in Norway and Sweden

Vinge has advised a consortium comprising Fredensborg AS, Fredensborg Bolig AS, Norwegian Property ASA and Union Real Estate Fund III Holding AS in its acquisition of Veidekke’s property development operation in Norway and Sweden

Veidekke has signed an agreement with a consortium comprising Fredensborg AS, Fredensborg Bolig AS, Norwegian Property ASA and Union Real Estate Fund III Holding AS concerning the consortium’s acquisition of Veidekke’s property development operation in Norway and Sweden against a payment of NOK 7.7 billion on a debt-free basis. Closing of the transaction is expected to take place in September 2020.

Vinge’s team consisted of, among others, Assur Badur, Frida Ställborn, Karolina Cohrs and Olof Löfvenberg (Real Property and Environment), Johan Winnerblad, Linda Sengul and Vilhelm Rondahl (M&A), Albert Wållgren, Ludvig Wettergren and Viktor Lennartsson (Financing), Lisa Hörnqvist (Commerical Agreements and IT), Ebba Svenburg (Employment) and the VDR-assistants Jessica Öijer and Carl Bruneheim.

Advokatfirmaet Thommessen has been the consortium’s lead legal counsel in the transaction.

 

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026